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a Kinder side of 
Red tides?
Investigators conducting a decade-long study 
into how Florida’s “red tide” algal blooms 
affect human health have discovered several 
compounds that counteract the toxins pro-
duced by the red tide dinoflagellate, Karenia 
brevis. In an intriguing twist, they are now 
developing one of these compounds, breve-
nal, as a potential treatment for cystic fibrosis 
(CF)  and  chronic  obstructive  pulmonary 
disease  (COPD).  In  cellular  and  animal 
models  brevenal  appears  far  more  potent 
than existing drugs for CF and COPD and 
exhibits the unique quality of both suppress-
ing inflammation and boosting mucociliary 
clearance.
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The investigators spent five years identi-
fying compounds produced by K. brevis that 
cause classic red tide symptoms of broncho-
constriction,  watering  eyes,  and  slowed 
mucociliary clearance. “Then we expanded 
the study to characterize all the degradation 
products, the side products, and coproducts 
from the biosynthetic machinery that could 
also be airborne, as we thought these might 
have  some  effect  on  people,”  says  Dan 
Baden,  director  of  the  Center  for  Marine 
Science at the University of North Carolina, 
Wilmington, and principal investigator for 
the  National  Institute  of  Environmental 
Health Sciences grant beind the work. 
To  the  investigators’  surprise,  three 
compounds actually mitigated the classical 
red tide toxicities. That seemed to explain a 
theretofore baffling observation: at certain 
times  during  a  bloom,  red  tide  toxicities 
appear to abate despite K. brevis’ abundance 
in the waters, Baden says. 
The  most  promising  of  these  com-
pounds is brevenal.
2 In cellular and sheep 
models, brevenal is therapeutically active at 
nanogram  to  picogram  concentrations.  In 
comparison, amiloride and glucocorticoster-
oids, used to treat CF and COPD, are active 
at microgram to milligram doses. Moreover, 
even  the  highest  doses  of  brevenal  tested 
caused no sign of irritation in the airways 
or other toxicity, says investigator William 
M. Abraham, director of research at Mount 
Sinai Medical Center, Miami Beach.
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Animal  tests  showed  the  compound 
had  two  effects  that  Abraham  says  are 
especially useful in diseases where there is 
impaired  mucus  clearance.  First,  it  stimu-
lated normal mucociliary clearance. Second, 
it  blocked  the  mucociliary-slowing  effect 
of human neutrophil elastase administered 
to  the  animals.  Neutrophil  elastase,  an 
immune  mediator,  is  often  overproduced 
in respiratory diseases such as COPD and 
CF, making mucus thick and sticky. “The 
newest [unpublished] information we have 
is that brevenal reduces the recruitment of 
neutrophils  to  the  airway  in  response  to 
elastase,  making  brevenal  a  molecule  that 
has both mucociliary and antiinflammatory 
activity,” Abraham says.
Baden  says  brevenal  interacts  with  a 
previously  undescribed  therapeutic  target.
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It is also the only known example of an algal 
compound  that  counteracts  toxins 
produced  by  the  same  microorgan-
ism, according to Michael Twiner, an 
assistant professor of biology in the 
University of Michigan Department 
of  Natural  Sciences,  who  was  not 
involved in the research. 
Brevenal’s novelty makes it attrac-
tive  from  a  business  point  of  view, 
Baden  says,  and  its  chemistry,  uses, 
and  derivatives  have  been  patented. 
Marine  Biotechnology  in  North 
Carolina (MARBIONC), a unit with-
in the Center for Marine Science, has 
teamed up with Ocean Therapeutics of 
Cary, North Carolina, to develop and 
commercialize the compound. Ocean 
Therapeutics has an exclusive license 
to  access  the  library  of  compounds 
developed  by  MARBIONC,  which 
Brian Dickson, Ocean Therapeutics’ 
chief  medical  officer,  describes  as 
unique  in  including  organisms  from 
hydrothermal vents and other locations 
where organisms must adapt to physiologi-
cally stressful conditions.
John E. Baatz, a professor in the Depart-
ment  of  Pediatrics,  Medical  University  of 
South  Carolina,  notes  the  animal  studies 
used very small numbers (4–8 in most cases), 
and he is not sanguine about using brevenal 
for COPD due to multiple complex—and 
incompletely understood—mechanisms act-
ing in that disease. Animal studies to date 
have  focused  on  toxicologic  and  morpho-
logic responses to a single dose of brevenal, 
he says, whereas multiple doses would likely 
be required to treat CF or COPD. 
Furthermore,  Baatz  says,  “[Although] 
cystic fibrosis is a disease for which brevenal 
treatment  appears  to  be  a  potential  treat-
ment option, it will likely be more expensive, 
require multiple dosing, and not necessarily 
[be] more effective than other pharmaceu-
ticals. I would need a little more persuasive 
data to see otherwise.” 
Dickson sees a different challenge in the 
offing. For ethical reasons, CF drugs have 
to be tested in adult patients, but mucous 
membranes  thicken  with  age.  “Getting  a 
drug across a thick mucosal membrane is 
quite difficult,” he explains. Yet, a drug that 
fails in an adult might well prove powerfully 
effective for a child because “young children 
[with  CF]  have  pretty  normal  mucosa.” 
Dickson also points out that, if effective, this 
drug would provide only symptomatic relief 
for  CF  patients.  “While  this  is  clinically 
important,” he says, “most other research in 
this area is looking for the Holy Grail such 
as a treatment for the root cause.” 
Generally, Dickson says, about 30% of 
drugs that show this much promise at this 
stage get to market. But if the drug, now 
about eight months from the end of preclini-
cal testing, should pass muster with the U.S. 
Food and Drug Administration, its status as 
an orphan drug
5 could result in its getting 
on the market within five years. 
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We always want to see what is hidden by what we see.
René Magritte, artist (1898–1967)
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Red tide off the U.S. West Coast.